CNBC Stock Blog
- Greek Exit Could Trigger 50% Fall in Euro Stocks: Analyst
- Big Stock Upside for Hudson City Deal: Analyst
- 5 High-Yield Stocks Ready to Boost Dividends
- Option Bulls Take Another Shot on Idenix
- Top 20 European Stocks for Crisis Time: Strategist
- Hewlett-Packard Faces a ‘Dogfight’ for Talent: Analyst
- DuckDuckGo Cooks Google’s Goose: Analyst
- General Electric’s $4.5 Billion Dividend Slated for Buybacks
ABOUT THE CNBC STOCK BLOG
ART CASHIN
RSS FEED
4 Stocks to Benefit From Health Care Reform: Strategist
Text Size 
CNBC.com Writer
Senate Democrats came to an agreement on Tuesday to replace the controversial government-run public insurance option with a scaled-back non-profit plan. So which companies in the health care sector are worth investing in? John Sullivan, director of research and health care investment strategist at Leerink Swann, shared his insight.
“The landscape is becoming clearer,” Sullivan told CNBC.
“Health care reform is within a few months of being resolved and, as it is, investors are coming back to the health care sector. At the current valuations of the health care sector, you can definitely pick winners and losers, even as health care reform is not completely reformed.”
Sullivan said health care stocks have been underowned, and investors will likely return to the larger companies with a lot of liquidity.
“Both Pfizer and Merck, coming off of big acquisitions, are very much in charge of their own earnings over the next couple of years as they implement cross-control initiatives. Investors will be very comfortable with what they see in U.S. drug company earnings over the next several quarters,” he said.
Sullivan Likes:
Pfizer [PFE
Loading...
()
]
Merck [MRK
Loading...
()
]
WellPoint [WLP
Loading...
()
]
Cigna [CI
Loading...
()
]
______________________________
More Sector Opinions:
______________________________
CNBC Data Pages:
______________________________
CNBC Slideshows:
______________________________
______________________________
Disclosures:
In the past 12 months, Sullivan’s firm has received compensation for providing non-securities services to Pfizer.
______________________________
Data is a real-time snapshot *Data is delayed at least 15 minutes
